New combo therapy offers hope for hard-to-treat nose cancer

NCT ID NCT07528183

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests a new treatment for people whose nose and throat cancer has returned and cannot be removed with surgery. The treatment combines an immunotherapy drug (PD-1 antibody) with two chemotherapy drugs, followed by targeted radiation. The goal is to see if this approach can help control the cancer and improve survival. The study will include 86 adults whose cancer shrank after initial chemo-immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCINOMA (NPC)

Contacts and locations

Locations

Fujian Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, China
Guangxi Medical University Cancer Hospital
NOT_YET_RECRUITING

Nanning, Guangxi, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.